Optical

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board

Retrieved on: 
Monday, April 8, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Faculty, Medical University of Vienna, Part, Patient, Queen's University, Optometry, Queen's University Belfast, CAB, MD, Royal Victoria Hospital, Laborie (company), Medical school, Therapy, Retina, Safety, AMD, Geographic atrophy, Pharmaceutical industry

Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • The Company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.
  • “We are excited that results from Part 1 of the US Phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, M.D., Aviceda’s Co-founder and CEO.
  • “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

Retrieved on: 
Tuesday, April 9, 2024
Physical Therapy, Technology, Managed Care, Health, Optical, Health Technology, Medical Devices, Photography, Software, Artificial Intelligence, Telemedicine, Virtual Medicine, Research, Diagnosis, Glaucoma, CE, Patient, Hospital, ARVO, IPredict, Paratriathlon, TGA, AMD, Diabetic retinopathy

The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.

Key Points: 
  • The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.
  • The entire test which includes color retinal imaging and the automated AI-based glaucoma report generation can easily and reliably be completed within 5 minutes.
  • Glaucoma detection offers an overall accuracy of 94.3% for identifying an individual with glaucoma.
  • iPredict’s glaucoma detection model can be used as follows:
    iPredict-glaucoma report will produce which will indicate referable (i.e., early to severe glaucoma) or non-referable glaucoma (not glaucoma).

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Retrieved on: 
Monday, April 8, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Wolfram syndrome, Medication, Metabolism, Patient, AMX0035, Samuel, Immunology, Doctor of Philosophy, MD, Trial of the century, Amylyx Pharmaceuticals, Division, Disorder, Pathology, Pharmaceutical industry

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Key Points: 
  • A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.
  • Dr. Fumihiko Urano is a physician and medical researcher specializing in Wolfram syndrome.
  • Dr. Urano is a driving force in the study of Wolfram syndrome and related disorders, including WFS1-related disorders/Wolfram-like disorders.
  • As director of the Wolfram Syndrome Clinic and the Wolfram Syndrome International Registry & Clinical Study at Washington University, Dr. Urano treats patients with Wolfram syndrome and related disorders, and leads basic science, clinical, translational, and interventional studies of Wolfram syndrome and related disorders.

Alcon Publishes Agenda for 2024 Annual General Meeting

Retrieved on: 
Sunday, April 7, 2024
Optical, Health, Surgery, Medical Devices, AGM, Executive Committee, Bank statement, Commerce, Annual general meeting, CHF, Hearing, Report

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024.

Key Points: 
  • Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024.
  • The company looks forward to hearing directly from its shareholders at this open format meeting.
  • The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters.
  • Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023
    3.

Global Allergy Conjunctivitis Market Projected to Reach $3.2 Billion by 2028, Driven by Increasing Allergies and Technological Innovations - Long-term Forecast to 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Health, Optical, Patient, Allergy, Research, Growth, Prevalence, Allergic conjunctivitis, Pollutant, Allergen

The global allergy conjunctivitis market is set to grow from $2.4 billion in 2023 to an estimated $3.2 billion in 2028, demonstrating a robust compound annual growth rate (CAGR) of 5.9%.

Key Points: 
  • The global allergy conjunctivitis market is set to grow from $2.4 billion in 2023 to an estimated $3.2 billion in 2028, demonstrating a robust compound annual growth rate (CAGR) of 5.9%.
  • This growth is fueled by a rise in the global burden of allergies, advancements in personalized medicine, and an expanding elderly population.
  • Innovation in biotechnological research and wider healthcare access in developing regions also contribute to the market's upward trajectory.
  • This noteworthy expansion of the allergy conjunctivitis market reflects a concentrated effort to meet the healthcare needs of those suffering from ocular allergies.

Dry Eye Syndrome Market Set for Rapid Growth as Aging Population Demand Soars - Global Long-term Forecast to 2028 and 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
General Health, Pharmaceutical, Optical, Health, Diagnosis, Quality of life, DES, Research, Growth, Prevalence, Dry eye syndrome, Acquisition, Therapy, Ageing, Pharmaceutical industry

The "Dry Eye Syndrome Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry Eye Syndrome Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • Leveraging in-depth market data, the report delves into the extensive range of products designed to alleviate symptoms of Dry Eye Syndrome (DES), including innovative liquid drops, gel formulations, and advanced ointment solutions.
  • These developments reflect the market's response to growing global demand, providing relief and effective therapy for those affected by the condition.
  • Moreover, the report lends insight into the geographical nuances that manifest in the demand and service provision within the global Dry Eye Syndrome sector.

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on: 
Thursday, April 4, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points: 
  • GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
  • Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
  • GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
  • As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

EyeCare Partners Announces New Refractive Cataract Anterior Segment Fellowship and Launch of ECP Foundation

Retrieved on: 
Thursday, April 4, 2024
Optical, Surgery, Health, Other Education, Philanthropy, Education, Foundation, Training, Disease burden, Partner, ECP, RCAS, Density, Intraocular lens, Growth, Convention, Refractive surgery, Physician, ASCRS, Telecanthus, Knowledge, Research, Meibomian gland dysfunction, Fellow, Trifocal lenses, Science, Patient satisfaction, Cataract, Mentorship, Quality of life, Surgeon, Society, Ophthalmology, Nursing

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.

Key Points: 
  • EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
  • The company is launching two new initiatives to elevate eye care – the Refractive Cataract Anterior Segment (RCAS) Fellowship and the ECP Foundation.
  • This one-year program provides residency graduates comprehensive training in the latest advancements in refractive cataract and anterior segment surgeries.
  • “We implement this mission through three programs: ECP GIVES, ECP EDUCATES and ECP CARES,” said Amy Jones, ECP Foundation President.

GenSight Biologics Announces its 2024 Financial Calendar

Retrieved on: 
Thursday, April 4, 2024
Health, Genetics, Research, Science, Pharmaceutical, Optical, Biotechnology

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.

Key Points: 

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, April 4, 2024
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Inducement, Employment, Compensated emancipation, Therapy

The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.

Key Points: 
  • The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan.
  • The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date.
  • The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.